{"protocolSection": {"identificationModule": {"nctId": "NCT01018186", "orgStudyIdInfo": {"id": "106839"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study", "officialTitle": "A Randomized, Double-Blind, Double Dummy, Active Comparator, Parallel Group, Multicenter Study to Evaluate the Safety of Once-Daily Fluticasone Furoate/GW642444 Inhalation Powder for 52 Weeks in Adolescent and Adult Subjects With Asthma"}, "statusModule": {"statusVerifiedDate": "2018-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-10-19"}, "primaryCompletionDateStruct": {"date": "2011-05-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-05-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-11-05", "studyFirstSubmitQcDate": "2009-11-19", "studyFirstPostDateStruct": {"date": "2009-11-23", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-06-06", "resultsFirstSubmitQcDate": "2013-08-22", "resultsFirstPostDateStruct": {"date": "2013-10-29", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2012-03-01", "dispFirstSubmitQcDate": "2012-03-01", "dispFirstPostDateStruct": {"date": "2012-03-05", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-01-18", "lastUpdatePostDateStruct": {"date": "2018-02-15", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the long-term safety of fluticasone furoate/GW642444"}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 503, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Fluticasone furoate/GW642444", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Fluticasone Furoate/GW642444"]}, {"label": "Fluticasone propionate", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Fluticasone propionate"]}], "interventions": [{"type": "DRUG", "name": "Fluticasone Furoate/GW642444", "description": "Combination inhaled corticosteroid and long-acting beta2-agonist", "armGroupLabels": ["Fluticasone furoate/GW642444"]}, {"type": "DRUG", "name": "Fluticasone propionate", "description": "Inhaled corticosteroid", "armGroupLabels": ["Fluticasone propionate"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During the Treatment Period", "description": "An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General Adverse AE/SAE module for a complete list of AEs and SAEs.", "timeFrame": "From the start of study medication until Visit 11 (Week 52)/Early Withdrawal"}, {"measure": "Number of Participants With Severe Asthma Exacerbations During the Treatment Period", "description": "A severe asthma exacerbation is defined as the deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. Courses of corticosteroids separated by 1 week or more were treated as separate severe exacerbations.", "timeFrame": "From the start of study medication until Visit 11 (Week 52)/Early Withdrawal"}, {"measure": "Change From Baseline in Albumin and Total Protein at Week 12, Week 28, and Week 52/Early Withdrawal", "description": "Blood samples were collected for the measurement of albumin and total protein values at the following scheduled time points: Baseline, Week 12, Week 28, and Week 52/Early Withdrawal. The Baseline value is defined as the most recent recorded value at Screening or prior to Day 1. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "timeFrame": "Baseline; Week 12, Week 28, and Week 52/Early Withdrawal"}, {"measure": "Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatine Kinase (CK), and Gamma Glutamyltransferase (GGT) at Week 12, Week 28, and Week 52/Early Withdrawal", "description": "Blood samples were collected for the measurement of ALP, ALT, AST, CK, and GGT values at the following scheduled time points: Baseline, Week 12, Week 28, and Week 52/Early Withdrawal. The Baseline value is defined as the most recent recorded value at Screening or prior to Day 1. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "timeFrame": "Baseline; Week 12, Week 28, and Week 52/Early Withdrawal"}, {"measure": "Change From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, and Creatinine at Week 12, Week 28, and Week 52/Early Withdrawal", "description": "Blood samples were collected for the measurement of direct bilirubin, indirect bilirubin, total bilirubin, and creatinine values at the following scheduled time points: Baseline, Week 12, Week 28, and Week 52/Early Withdrawal. The Baseline value is defined as the most recent recorded value at Screening or prior to Day 1. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "timeFrame": "Baseline; Week 12, Week 28, and Week 52/Early Withdrawal"}, {"measure": "Change From Baseline in Chloride, Carbon Dioxide Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) at Week 12, Week 28, and Week 52/Early Withdrawal", "description": "Blood samples were collected for the measurement of chloride, carbon dioxide (CO2) content/bicarbonate, glucose, potassium, sodium, and urea/BUN values at the following scheduled time points: Baseline, Week 12, Week 28, and Week 52/Early Withdrawal. The Baseline value is defined as the most recent recorded value at Screening or prior to Day 1. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "timeFrame": "Baseline; Week 12, Week 28, and Week 52/Early Withdrawal"}, {"measure": "Change From Baseline in the Percentage of Basophils, Eosinophils, Hematocrit, Lymphocytes, Monocytes, and Segmented Neutrophils in the Blood at Week 12, Week 28, and Week 52/Early Withdrawal", "description": "Blood samples were collected for the measurement of the percentage of basophils, eosinophils, hematocrit, lymphocytes, monocytes, and segmented neutrophils in the blood at the following scheduled time points: Baseline, Week 12, Week 28, and Week 52/Early Withdrawal. The Baseline value is defined as the most recent recorded value at Screening or prior to Day 1. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "timeFrame": "Baseline; Week 12, Week 28, and Week 52/Early Withdrawal"}, {"measure": "Change From Baseline in Eosinophil Count, Total Absolute Neutrophil Count (ANC), Platelet Count, and White Blood Cell (WBC) Count at Week 12, Week 28, and Week 52/Early Withdrawal", "description": "Blood samples were collected to determine the eosinophil count, total ANC, platelet count, and WBC count at the following scheduled time points: Baseline, Week 12, Week 28, and Week 52/Early Withdrawal. The Baseline value is defined as the most recent recorded value at Screening or prior to Day 1. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "timeFrame": "Baseline; Week 12, Week 28, and Week 52/Early Withdrawal"}, {"measure": "Change From Baseline in Hematocrit at Week 12, Week 28, and Week 52/Early Withdrawal", "description": "Blood samples were collected for the measurement of hematocrit values at the following scheduled time points: Baseline, Week 12, Week 28, and Week 52/Early Withdrawal. The Baseline value is defined as the most recent recorded value at Screening or prior to Day 1. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "timeFrame": "Baseline; Week 12, Week 28, and Week 52/Early Withdrawal"}, {"measure": "Change From Baseline in Hemoglobin at Week 12, Week 28, and Week 52/Early Withdrawal", "description": "Blood samples were collected for the measurement of hemoglobin values at the following scheduled time points: Baseline, Week 12, Week 28, and Week 52/Early Withdrawal. The Baseline value is defined as the most recent recorded value at Screening or prior to Day 1. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "timeFrame": "Baseline; Week 12, Week 28, and Week 52/Early Withdrawal"}, {"measure": "Number of Participants With the Indicated Shift From Baseline to High, Normal or no Change, and Low Post-Baseline Values for Urinary Cortisol Excretion", "description": "A 24-hour urine sample was collected for the measurement of 24-hour urinary cortisol excretion (UCE) at the following scheduled time points: Baseline, Week 12, Week 28, and Week 52/Early Withdrawal. Any visit post-baseline (AVPB) value was derived using laboratory assessments performed at scheduled, unscheduled, and Early Withdrawal visits. Participants who had a shift from Baseline in their post-Baseline UCE values relative to the normal range, are presented in the \"To high and To low\" categories. Participants whose post-Baseline UCE values were unchanged (e.g., High to High) or whose value became normal, are presented in the \"To normal or no change\" category. The normal range for UCE is defined as: 11 to 138 nanomoles per 24 hours (nmol/24 hr) for participants \\>=18 years of age, 8.3 to 151.7 nmol/24 hr for participants 14 to 17 years of age, and 2.8 to 124.2 nmol/24 hr for participants 12 and 13 years of age.", "timeFrame": "Baseline; Week 12, Week 28, and Week 52/Early Withdrawal"}, {"measure": "Ratio of 24-hour Urinary Cortisol Excretion at Week 12 to Baseline", "description": "A 24-hour urine sample was collected, and the least square geometric mean (LSGM) for 24-hour urinary cortisol excretion (UCE) was calculated at Baseline and at Week 12. The ratio of the Week 12 LSGM to the Baseline LSGM was calculated as the value at Week 12 divided by the value at Baseline. Analysis was performed using analysis of covariance (ANCOVA) with covariates of region, sex, age, treatment, and the log of the Baseline values.", "timeFrame": "Baseline and Week 12"}, {"measure": "Ratio of 24-hour Urinary Cortisol Excretion at Week 28 to Baseline", "description": "A 24-hour urine sample was collected, and the LSGM for 24-hour UCE was calculated at Baseline and at Week 28. The ratio of the Week 28 LSGM to the Baseline LSGM was calculated as the value at Week 28 divided by the value at Baseline. Analysis was performed using ANCOVA with covariates of region, sex, age, treatment, and the log of the Baseline values.", "timeFrame": "Baseline and Week 28"}, {"measure": "Ratio of 24-hour Urinary Cortisol Excretion at Week 52 to Baseline", "description": "A 24-hour urine sample was collected, and the LSGM for 24-hour UCE was calculated at Baseline and at Week 52. The ratio of the Week 52 LSGM to the Baseline LSGM was calculated as the value at Week 52 divided by the value at Baseline. Analysis was performed using ANCOVA with covariates of region, sex, age, treatment, and the log of the Baseline values.", "timeFrame": "Baseline and Week 52"}, {"measure": "Number of Participants With Evidence of Oral Candidiasis at Any Time Post-Baseline", "description": "A detailed oropharyngeal examination was done at all clinic visits for visual/clinical evidence of oral candidiasis over the entire Treatment Period (worst case any time post-Baseline). For participants with visual/clinical evidence of candidiasis during the Treatment Phase of the study, a culture swab was taken and analyzed for infection.", "timeFrame": "From Baseline until Visit 11/Early Withdrawal (52 weeks)"}, {"measure": "Maximum Change From Baseline in Systolic Blood Pressure (SBP) and Minimum Change From Baseline in Diastolic Blood Pressure (DBP)", "description": "SBP and DBP were measured at the following scheduled time points: Screening, Day 1, Week 2, Week 4, Week 8, Week 12, Week 20, Week 28, Week 36, Week 44, and Week 52/Early Withdrawal. Baseline is defined as the Visit 1 (screening) value. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline. Maximum and minimum change from Baseline for any post-Baseline visit was derived using all scheduled, unscheduled, and Early Withdrawal visits.", "timeFrame": "From Baseline until Visit 11/Early Withdrawal (52 weeks)"}, {"measure": "Maximum Change From Baseline in Pulse Rate", "description": "Pulse rate was measured at the following scheduled time points: Screening, Day 1, Week 2, Week 4, Week 8, Week 12, Week 20,Week 28, Week 36, Week 44, and Week 52/Early Withdrawal. Baseline is defined as the Visit 1 (screening) value. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline. Maximum change from Baseline for any post-Baseline visit was derived using all scheduled, unscheduled, and Early Withdrawal visits.", "timeFrame": "From Baseline until Visit 11/Early Withdrawal (52 weeks)"}, {"measure": "Number of Participants With the Indicated Change From Baseline in Lens Opacities Classification System, Version III (LOCS III) Posterior Subcapsular Opacity (P) at Week 28 and Week 52", "description": "P is defined as the opacification at the back of the lens adjacent to the capsule (or bag) in which the lens sits. An event of P is defined as an increase of \\>=0.3 from Baseline in LOCS III grade for P in either eye at any time post-Baseline. Per LOC III, P ranges from 0.1 (clear or colorless) to 5.9 (very opaque). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "timeFrame": "Baseline; Week 28, and Week 52"}, {"measure": "Number of Participants With the Indicated Change From Baseline in Intraocular Pressure (IOP) at Week 28 and Week 52", "description": "Intraocular pressure (IOP) is the fluid pressure inside the eye. IOP was measured twice for each eye at Baseline, Week 28, and Week 52 using Goldmann Applanation tonometry. The second IOP reading was used for analysis. The number of participants with a change from Baseline in IOP of \\<0 mmHg, \\>=0 to \\<4 mmHg, \\>=4 to \\<7 mmHg, \\>=7 to \\<11 mmHg, and \\>=11 mmHg are presented. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "timeFrame": "Baseline; Week 28 and Week 52"}, {"measure": "Change From Baseline in Horizontal Cup-to-disc Ratio at Week 28 and Week 52", "description": "Funduscopic examination was performed at Baseline, Week 28, and Week 52 to measure the horizontal cup-to-disc ratio of both eyes. The horizontal cup-to-disc ratio is the ratio of the horizontal diameter of the physiological cup to that of the horizontal diameter of the optic disc. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "timeFrame": "Baseline; Week 28 and Week 52"}, {"measure": "Number of Participants With the Indicated Change From Baseline in Lens Opacities Classification System, Version III (LOCS III) Cortical Opacity (C) at Week 28 and Week 52", "description": "C is defined as the opacification of the cortex (outer layer) of the lens. Per LOC III, C ranges from 0.1 (clear or colorless) to 5.9 (very opaque). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "timeFrame": "Baseline; Week 28 and Week 52"}, {"measure": "Change From Baseline in Lens Opacities Classification System, Version III (LOCS III) Nuclear Color (NC) at Week 28 and Week 52", "description": "NC is the color of the nucleus (central layer) of the lens. Per LOC III, NC ranges from 0.1 (clear or colorless) to 6.9 (very opaque or brunescent). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "timeFrame": "Baseline; Week 28 and Week 52"}, {"measure": "Change From Baseline in Lens Opacities Classification System, Version III (LOCS III) Nuclear Opalescence (NO) at Week 28 and Week 52", "description": "NO is the opalescence of the nucleus (central layer) of the lens. Per LOC III, NO ranges from 0.1 (clear or colorless) to 6.9 (very opaque or brunescent). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "timeFrame": "Baseline; Week 28 and Week 52"}, {"measure": "Change From Baseline in the Logarithm of the Minimum Angle of Resolution (LogMAR) Visual Acuity at Week 28 and Week 52", "description": "Visual acuity is defined as the acuteness or clearness of vision. The minimum angle of resolution (MAR) is the angle a viewed object subtends at the eye, usually stated in degrees/minutes of arc. Visual acuity was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) charts in decimal numbers. The LogMAR scale is used to express the visual acuity in a linear scale as the logarithm to base 10 of the MAR. A lower score indicates better visual acuity; visual acuity decreases with an increasing score. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "timeFrame": "Baseline; Week 28 and Week 52"}, {"measure": "Maximum Change From Baseline in the QT Interval Using Bazett's Correction (QTcB) and QT Interval Using Fridericia's Correction (QTcF)", "description": "The QT interval is an electrocardiogram (ECG) parameter that represents the electrical depolarization and repolarization of the left and right ventricles of the heart. The QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the ECG. Corrected QT (QTc) is the QT interval corrected for heart rate by using Bazett's formula (QTcB) and Fridericia's formula (QTcF). 12-lead ECG measurements were perfomed at the following scheduled time points: Baseline; Week 2, Week 12, Week 28, and Week 52/Early Withdrawal. The Baseline value is defined as the value taken pre-dose at screening. The maximum post-Baseline value was derived using all scheduled, unscheduled, and Early Withdrawal ECG assessments. Maximum change from Baseline was calculated as the maximum post-Baseline value minus the value at Baseline.", "timeFrame": "Baseline; Week 2, Week 12, Week 28, and Week 52/Early Withdrawal"}, {"measure": "Mean 24 Hour Holter Heart Rate for Participants With at Least 16 Hours of Recorded Data", "description": "Twenty-four hour Holter monitors were obtained using a 12-lead Holter monitor. The Holter monitor is worn by the participant for 24 hours, and the monitor continuously records the heart's rhythm while the monitor is worn. At the end of the 24 hour period, the data from the monitor are downloaded and transmitted to the centralized vendor for analysis and interpretation by a licensed cardiologist.", "timeFrame": "0-24 hours at Screening, Day 1, Week 28, and Week 52"}, {"measure": "Maximum 24 Hour Holter Heart Rate for Participants With at Least 16 Hours of Recorded Data", "description": "Twenty-four hour Holter monitors were obtained using a 12-lead Holter monitor. Holter monitor data were transmitted to a centralized vendor for analysis and interpretation by a licensed cardiologist.", "timeFrame": "0-24 hours at Screening, Day 1, Week 28, and Week 52"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Clinical diagnosis of asthma\n* Reversibility FEV1 of twelve percent or greater and two hundred milliliters and greater approximately ten to forty minutes following two to four inhalations of albuterol\n* FEV1 greater than or equal to fifty percent of predicted\n* Currently using moderate to high dose inhaled corticosteroid therapy\n\nExclusion Criteria:\n\n* History of life threatening asthma\n* Respiratory infection or oral candidiasis\n* Asthma exacerbation\n* Uncontrolled disease or clinical abnormality\n* Allergies\n* Taking another investigational medication or prohibited medication", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Oxford", "state": "Alabama", "zip": "36203", "country": "United States", "geoPoint": {"lat": 33.61427, "lon": -85.83496}}, {"facility": "GSK Investigational Site", "city": "Huntington Beach", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "GSK Investigational Site", "city": "Mission Viejo", "state": "California", "zip": "92691", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"facility": "GSK Investigational Site", "city": "Rolling Hills Estates", "state": "California", "zip": "90274", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "GSK Investigational Site", "city": "Stockton", "state": "California", "zip": "95207", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "GSK Investigational Site", "city": "Bethesda", "state": "Maryland", "zip": "20814", "country": "United States", "geoPoint": {"lat": 38.98067, "lon": -77.10026}}, {"facility": "GSK Investigational Site", "city": "Bellevue", "state": "Nebraska", "zip": "68123-4303", "country": "United States", "geoPoint": {"lat": 41.13667, "lon": -95.89084}}, {"facility": "GSK Investigational Site", "city": "Skillman", "state": "New Jersey", "zip": "08558", "country": "United States", "geoPoint": {"lat": 40.42011, "lon": -74.7146}}, {"facility": "GSK Investigational Site", "city": "Raleigh", "state": "North Carolina", "zip": "27607", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "GSK Investigational Site", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "GSK Investigational Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73103", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "GSK Investigational Site", "city": "Austin", "state": "Texas", "zip": "78750", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "GSK Investigational Site", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "GSK Investigational Site", "city": "El Paso", "state": "Texas", "zip": "79903", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "GSK Investigational Site", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "GSK Investigational Site", "city": "Waco", "state": "Texas", "zip": "76712", "country": "United States", "geoPoint": {"lat": 31.54933, "lon": -97.14667}}, {"facility": "GSK Investigational Site", "city": "South Burlington", "state": "Vermont", "zip": "05403", "country": "United States", "geoPoint": {"lat": 44.46699, "lon": -73.17096}}, {"facility": "GSK Investigational Site", "city": "Greenfield", "state": "Wisconsin", "zip": "53228", "country": "United States", "geoPoint": {"lat": 42.9614, "lon": -88.01259}}, {"facility": "GSK Investigational Site", "city": "Mannheim", "state": "Baden-Wuerttemberg", "zip": "68161", "country": "Germany", "geoPoint": {"lat": 49.4891, "lon": 8.46694}}, {"facility": "GSK Investigational Site", "city": "Bad Woerrishofen", "state": "Bayern", "zip": "86825", "country": "Germany"}, {"facility": "GSK Investigational Site", "city": "Potsdam", "state": "Brandenburg", "zip": "14469", "country": "Germany", "geoPoint": {"lat": 52.39886, "lon": 13.06566}}, {"facility": "GSK Investigational Site", "city": "Offenbach", "state": "Hessen", "zip": "63071", "country": "Germany", "geoPoint": {"lat": 50.10061, "lon": 8.76647}}, {"facility": "GSK Investigational Site", "city": "Dresden", "state": "Sachsen", "zip": "01067", "country": "Germany", "geoPoint": {"lat": 51.05089, "lon": 13.73832}}, {"facility": "GSK Investigational Site", "city": "Leipzig", "state": "Sachsen", "zip": "04103", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "GSK Investigational Site", "city": "Leipzig", "state": "Sachsen", "zip": "04357", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "GSK Investigational Site", "city": "Radebeul", "state": "Sachsen", "zip": "01445", "country": "Germany", "geoPoint": {"lat": 51.10654, "lon": 13.66047}}, {"facility": "GSK Investigational Site", "city": "Reinfeld", "state": "Schleswig-Holstein", "zip": "23858", "country": "Germany", "geoPoint": {"lat": 53.83184, "lon": 10.49126}}, {"facility": "GSK Investigational Site", "city": "Schmoelln", "state": "Thueringen", "zip": "04626", "country": "Germany"}, {"facility": "GSK Investigational Site", "city": "Berlin", "zip": "10365", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "GSK Investigational Site", "city": "Berlin", "zip": "10367", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "GSK Investigational Site", "city": "Berlin", "zip": "10717", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "GSK Investigational Site", "city": "Berlin", "zip": "13086", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "GSK Investigational Site", "city": "Berlin", "zip": "13581", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "GSK Investigational Site", "city": "Bangkok", "zip": "10330", "country": "Thailand", "geoPoint": {"lat": 13.75398, "lon": 100.50144}}, {"facility": "GSK Investigational Site", "city": "Bangkok", "zip": "10400", "country": "Thailand", "geoPoint": {"lat": 13.75398, "lon": 100.50144}}, {"facility": "GSK Investigational Site", "city": "Chiangmai", "zip": "50200", "country": "Thailand", "geoPoint": {"lat": 18.79038, "lon": 98.98468}}, {"facility": "GSK Investigational Site", "city": "Khon Kaen", "zip": "40002", "country": "Thailand", "geoPoint": {"lat": 16.44671, "lon": 102.833}}, {"facility": "GSK Investigational Site", "city": "Dnipropetrovsk", "zip": "49027", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "GSK Investigational Site", "city": "Dnipropetrovsk", "zip": "49051", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "GSK Investigational Site", "city": "Donetsk", "zip": "83017", "country": "Ukraine", "geoPoint": {"lat": 48.023, "lon": 37.80224}}, {"facility": "GSK Investigational Site", "city": "Donetsk", "zip": "83099", "country": "Ukraine", "geoPoint": {"lat": 48.023, "lon": 37.80224}}, {"facility": "GSK Investigational Site", "city": "Kyiv", "zip": "02091", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Kyiv", "zip": "02660", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Kyiv", "zip": "03038", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Kyiv", "zip": "04050", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Simferopol", "zip": "95034", "country": "Ukraine", "geoPoint": {"lat": 44.95719, "lon": 34.11079}}]}, "referencesModule": {"references": [{"pmid": "23440247", "type": "BACKGROUND", "citation": "Busse WW, O'Byrne PM, Bleecker ER, Lotvall J, Woodcock A, Andersen L, Hicks W, Crawford J, Jacques L, Apoux L, Bateman ED. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial. Thorax. 2013 Jun;68(6):513-20. doi: 10.1136/thoraxjnl-2012-202606. Epub 2013 Feb 25."}], "seeAlsoLinks": [{"label": "Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.", "url": "https://www.clinicalstudydatarequest.com"}], "availIpds": [{"id": "106839", "type": "Individual Participant Data Set", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "106839", "type": "Study Protocol", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "106839", "type": "Informed Consent Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "106839", "type": "Annotated Case Report Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "106839", "type": "Clinical Study Report", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "106839", "type": "Dataset Specification", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "106839", "type": "Statistical Analysis Plan", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants meeting all inclusion criteria and none of the exclusion criteria during the screening visit entered a 2-week Run-in Period for completion of Baseline safety evaluations and to obtain Baseline measures of asthma status. At Visit 2, participants were randomized to a 52-week Double-blind Treatment Period.", "recruitmentDetails": "Participants were randomized in a 2:2:1 ratio to Fluticasone Furoate/GW642444 Inhalation Powder (two strengths: 200/25 micrograms (\u00b5g) once daily and 100/25 \u00b5g once daily) and fluticasone propionate 500 \u00b5g twice daily, respectively.", "groups": [{"id": "FG000", "title": "Current Asthma Therapy at a Fixed Dose", "description": "Participants were instructed to continue using an approved fixed dose of an inhaled corticosteroid (ICS) with or without an additional controller medication (i.e., long-acting beta-agonist, leukotriene modifier, etc.) for 2 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Run-in Period."}, {"id": "FG001", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF)/Vilanterol (VI) 100/25 micrograms (\u00b5g) inhalation powder once daily (OD) in the evening via the Dry Powder Inhaler (DPI), plus a placebo via DISKUS/ACCUHALER twice daily (BID), for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "FG002", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "FG003", "title": "FP 500 \u00b5g BID", "description": "Participants received Fluticasone Propionate (FP) 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "periods": [{"title": "2-week Run-in Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "617"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "503"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "114"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Did Not Meet Continuation Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "97"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "52-week Double-blind Treatment Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "201"}, {"groupId": "FG002", "numSubjects": "202"}, {"groupId": "FG003", "numSubjects": "100"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "161"}, {"groupId": "FG002", "numSubjects": "161"}, {"groupId": "FG003", "numSubjects": "71"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "40"}, {"groupId": "FG002", "numSubjects": "41"}, {"groupId": "FG003", "numSubjects": "29"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Protocol-defined Stopping Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "14"}, {"groupId": "FG002", "numSubjects": "16"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "3"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "9"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF)/Vilanterol (VI) 100/25 micrograms (\u00b5g) inhalation powder once daily (OD) in the evening via the Dry Powder Inhaler (DPI), plus a placebo via DISKUS/ACCUHALER twice daily (BID), for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "BG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "BG002", "title": "FP 500 \u00b5g BID", "description": "Participants received Fluticasone Propionate (FP) 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "201"}, {"groupId": "BG001", "value": "202"}, {"groupId": "BG002", "value": "100"}, {"groupId": "BG003", "value": "503"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "39.7", "spread": "15.85"}, {"groupId": "BG001", "value": "38.5", "spread": "15.64"}, {"groupId": "BG002", "value": "38.6", "spread": "15.97"}, {"groupId": "BG003", "value": "39.0", "spread": "15.77"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "130"}, {"groupId": "BG001", "value": "124"}, {"groupId": "BG002", "value": "62"}, {"groupId": "BG003", "value": "316"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "71"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "38"}, {"groupId": "BG003", "value": "187"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "African American/African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "38"}]}]}, {"title": "Asian - East Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}]}]}, {"title": "Asian - South East Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "50"}, {"groupId": "BG001", "value": "51"}, {"groupId": "BG002", "value": "24"}, {"groupId": "BG003", "value": "125"}]}]}, {"title": "Asian - Mixed Race", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}]}]}, {"title": "White - Arabic/North African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "5"}]}]}, {"title": "White - White/Caucasian/European Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "129"}, {"groupId": "BG001", "value": "132"}, {"groupId": "BG002", "value": "68"}, {"groupId": "BG003", "value": "329"}]}]}, {"title": "White - Mixed Race", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "3"}]}]}, {"title": "Mixed Race", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During the Treatment Period", "description": "An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General Adverse AE/SAE module for a complete list of AEs and SAEs.", "populationDescription": "Intent-to-Treat (ITT) Population: all participants randomized to treatment who received at least one dose of study medication", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "From the start of study medication until Visit 11 (Week 52)/Early Withdrawal", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF)/Vilanterol (VI) 100/25 micrograms (\u00b5g) inhalation powder once daily (OD) in the evening via the Dry Powder Inhaler (DPI), plus a placebo via DISKUS/ACCUHALER twice daily (BID), for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received Fluticasone Propionate (FP) 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"title": "Any AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "139"}, {"groupId": "OG001", "value": "134"}, {"groupId": "OG002", "value": "73"}]}]}, {"title": "Any SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "7"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Severe Asthma Exacerbations During the Treatment Period", "description": "A severe asthma exacerbation is defined as the deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. Courses of corticosteroids separated by 1 week or more were treated as separate severe exacerbations.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "From the start of study medication until Visit 11 (Week 52)/Early Withdrawal", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "3"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Albumin and Total Protein at Week 12, Week 28, and Week 52/Early Withdrawal", "description": "Blood samples were collected for the measurement of albumin and total protein values at the following scheduled time points: Baseline, Week 12, Week 28, and Week 52/Early Withdrawal. The Baseline value is defined as the most recent recorded value at Screening or prior to Day 1. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the ITT Population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Grams per liter (G/L)", "timeFrame": "Baseline; Week 12, Week 28, and Week 52/Early Withdrawal", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"title": "Albumin, Week 12, n=172, 182, 87", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "2.69"}, {"groupId": "OG001", "value": "0.2", "spread": "2.87"}, {"groupId": "OG002", "value": "-0.5", "spread": "2.64"}]}]}, {"title": "Albumin, Week 28, n=180, 176, 79", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "2.68"}, {"groupId": "OG001", "value": "-0.3", "spread": "2.79"}, {"groupId": "OG002", "value": "-0.4", "spread": "2.76"}]}]}, {"title": "Albumin, Week 52, n=157, 159, 67", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "2.81"}, {"groupId": "OG001", "value": "-0.8", "spread": "2.72"}, {"groupId": "OG002", "value": "-0.5", "spread": "2.54"}]}]}, {"title": "Total Protein, Week 12, n=172, 182, 87", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "4.13"}, {"groupId": "OG001", "value": "-0.1", "spread": "4.50"}, {"groupId": "OG002", "value": "-0.6", "spread": "3.96"}]}]}, {"title": "Total Protein, Week 28, n=180, 176, 79", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "3.90"}, {"groupId": "OG001", "value": "-1.0", "spread": "4.47"}, {"groupId": "OG002", "value": "-0.5", "spread": "4.33"}]}]}, {"title": "Total Protein, Week 52, n=157, 159, 67", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "4.53"}, {"groupId": "OG001", "value": "-1.4", "spread": "4.60"}, {"groupId": "OG002", "value": "-1.0", "spread": "4.38"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatine Kinase (CK), and Gamma Glutamyltransferase (GGT) at Week 12, Week 28, and Week 52/Early Withdrawal", "description": "Blood samples were collected for the measurement of ALP, ALT, AST, CK, and GGT values at the following scheduled time points: Baseline, Week 12, Week 28, and Week 52/Early Withdrawal. The Baseline value is defined as the most recent recorded value at Screening or prior to Day 1. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the ITT Population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "International units per liter (IU/L)", "timeFrame": "Baseline; Week 12, Week 28, and Week 52/Early Withdrawal", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"title": "ALP, Week 12, n=158, 165, 84", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.0", "spread": "18.76"}, {"groupId": "OG001", "value": "-2.6", "spread": "29.65"}, {"groupId": "OG002", "value": "-4.7", "spread": "24.47"}]}]}, {"title": "ALP, Week 28, n=180, 176, 79", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "32.68"}, {"groupId": "OG001", "value": "-5.8", "spread": "30.56"}, {"groupId": "OG002", "value": "-5.7", "spread": "24.33"}]}]}, {"title": "ALP, Week 52, n=157, 157, 67", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.0", "spread": "30.67"}, {"groupId": "OG001", "value": "-7.2", "spread": "34.65"}, {"groupId": "OG002", "value": "-9.3", "spread": "27.54"}]}]}, {"title": "ALT, Week 12, n=172, 182, 87", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "10.43"}, {"groupId": "OG001", "value": "-0.2", "spread": "13.51"}, {"groupId": "OG002", "value": "-0.3", "spread": "12.03"}]}]}, {"title": "ALT, Week 28, n=180, 176, 79", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.6", "spread": "10.08"}, {"groupId": "OG001", "value": "-0.1", "spread": "10.59"}, {"groupId": "OG002", "value": "0.4", "spread": "11.96"}]}]}, {"title": "ALT, Week 52, n=157, 159, 67", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.8", "spread": "12.40"}, {"groupId": "OG001", "value": "-1.3", "spread": "11.13"}, {"groupId": "OG002", "value": "-0.1", "spread": "9.78"}]}]}, {"title": "AST, Week 12, n=171, 181, 87", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "8.07"}, {"groupId": "OG001", "value": "-0.3", "spread": "12.05"}, {"groupId": "OG002", "value": "0.3", "spread": "8.69"}]}]}, {"title": "AST, Week 28, n=179, 176, 79", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.4", "spread": "8.42"}, {"groupId": "OG001", "value": "-0.9", "spread": "11.60"}, {"groupId": "OG002", "value": "1.3", "spread": "10.65"}]}]}, {"title": "AST, Week 52, n=156, 158, 67", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.8", "spread": "8.78"}, {"groupId": "OG001", "value": "-1.9", "spread": "11.21"}, {"groupId": "OG002", "value": "-0.2", "spread": "9.22"}]}]}, {"title": "GGT, Week 12, n=172, 182, 87", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.9", "spread": "12.90"}, {"groupId": "OG001", "value": "-0.1", "spread": "18.23"}, {"groupId": "OG002", "value": "-1.7", "spread": "12.12"}]}]}, {"title": "GGT, Week 28, n=180, 176, 79", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.3", "spread": "33.79"}, {"groupId": "OG001", "value": "-0.6", "spread": "17.63"}, {"groupId": "OG002", "value": "-0.2", "spread": "11.85"}]}]}, {"title": "GGT, Week 52, n=157, 159, 67", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.7", "spread": "40.34"}, {"groupId": "OG001", "value": "-2.7", "spread": "15.99"}, {"groupId": "OG002", "value": "-0.5", "spread": "13.30"}]}]}, {"title": "Creatinine Kinase, Week 12, n=172, 181, 87", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.8", "spread": "92.06"}, {"groupId": "OG001", "value": "-11.5", "spread": "254.71"}, {"groupId": "OG002", "value": "-18.3", "spread": "223.59"}]}]}, {"title": "Creatinine Kinase, Week 28, n=180, 176, 79", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "spread": "68.72"}, {"groupId": "OG001", "value": "-9.9", "spread": "247.61"}, {"groupId": "OG002", "value": "15.3", "spread": "441.68"}]}]}, {"title": "Creatinine Kinase, Week 52, n=157, 159, 67", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "69.12"}, {"groupId": "OG001", "value": "-16.8", "spread": "266.48"}, {"groupId": "OG002", "value": "-27.7", "spread": "274.14"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, and Creatinine at Week 12, Week 28, and Week 52/Early Withdrawal", "description": "Blood samples were collected for the measurement of direct bilirubin, indirect bilirubin, total bilirubin, and creatinine values at the following scheduled time points: Baseline, Week 12, Week 28, and Week 52/Early Withdrawal. The Baseline value is defined as the most recent recorded value at Screening or prior to Day 1. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the ITT Population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Micromoles per liter (\u00b5mol/L)", "timeFrame": "Baseline; Week 12, Week 28, and Week 52/Early Withdrawal", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"title": "Direct bilirubin, Week 12, n=172, 182, 87", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "0.99"}, {"groupId": "OG001", "value": "-0.3", "spread": "0.98"}, {"groupId": "OG002", "value": "-0.2", "spread": "0.93"}]}]}, {"title": "Direct bilirubin, Week 28, n=180, 176, 79", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "0.97"}, {"groupId": "OG001", "value": "-0.2", "spread": "1.01"}, {"groupId": "OG002", "value": "-0.1", "spread": "0.94"}]}]}, {"title": "Direct bilirubin, Week 52, n=157, 159, 67", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "0.99"}, {"groupId": "OG001", "value": "-0.4", "spread": "1.00"}, {"groupId": "OG002", "value": "-0.2", "spread": "0.90"}]}]}, {"title": "Indirect bilirubin, Week 12, n=172, 182, 87", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.4", "spread": "3.11"}, {"groupId": "OG001", "value": "-0.8", "spread": "2.86"}, {"groupId": "OG002", "value": "-0.6", "spread": "3.04"}]}]}, {"title": "Indirect bilirubin, Week 28, n=180, 175, 79", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.3", "spread": "3.09"}, {"groupId": "OG001", "value": "-0.9", "spread": "2.87"}, {"groupId": "OG002", "value": "-0.4", "spread": "3.14"}]}]}, {"title": "Indirect bilirubin, Week 52, n=157, 159, 67", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.0", "spread": "3.08"}, {"groupId": "OG001", "value": "-1.6", "spread": "2.51"}, {"groupId": "OG002", "value": "-0.8", "spread": "2.68"}]}]}, {"title": "Total Bilirubin, Week 12, n=172, 182, 87", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.7", "spread": "3.62"}, {"groupId": "OG001", "value": "-1.1", "spread": "3.46"}, {"groupId": "OG002", "value": "-0.8", "spread": "3.44"}]}]}, {"title": "Total Bilirubin, Week 28, n=180, 175, 79", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.6", "spread": "3.61"}, {"groupId": "OG001", "value": "-1.2", "spread": "3.55"}, {"groupId": "OG002", "value": "-0.5", "spread": "3.46"}]}]}, {"title": "Total Bilirubin, Week 52, n=157, 159, 67", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.4", "spread": "3.58"}, {"groupId": "OG001", "value": "-2.0", "spread": "2.93"}, {"groupId": "OG002", "value": "-1.0", "spread": "3.14"}]}]}, {"title": "Creatinine, Week 12, n=172, 181, 87", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.00", "spread": "10.214"}, {"groupId": "OG001", "value": "3.18", "spread": "7.983"}, {"groupId": "OG002", "value": "3.99", "spread": "8.056"}]}]}, {"title": "Creatinine, Week 28, n=180, 176, 79", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.03", "spread": "19.264"}, {"groupId": "OG001", "value": "5.10", "spread": "10.316"}, {"groupId": "OG002", "value": "17.43", "spread": "92.175"}]}]}, {"title": "Creatinine, Week 52, n=157, 159, 67", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.74", "spread": "9.450"}, {"groupId": "OG001", "value": "3.14", "spread": "11.310"}, {"groupId": "OG002", "value": "3.32", "spread": "9.982"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Chloride, Carbon Dioxide Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) at Week 12, Week 28, and Week 52/Early Withdrawal", "description": "Blood samples were collected for the measurement of chloride, carbon dioxide (CO2) content/bicarbonate, glucose, potassium, sodium, and urea/BUN values at the following scheduled time points: Baseline, Week 12, Week 28, and Week 52/Early Withdrawal. The Baseline value is defined as the most recent recorded value at Screening or prior to Day 1. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the ITT Population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Millimoles per liter (mmol/L)", "timeFrame": "Baseline; Week 12, Week 28, and Week 52/Early Withdrawal", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"title": "Chloride, Week 12, n=172, 182, 87", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "3.43"}, {"groupId": "OG001", "value": "-0.4", "spread": "3.50"}, {"groupId": "OG002", "value": "0.1", "spread": "2.28"}]}]}, {"title": "Chloride, Week 28, n=180, 176, 79", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "2.50"}, {"groupId": "OG001", "value": "0.2", "spread": "2.73"}, {"groupId": "OG002", "value": "-0.1", "spread": "2.54"}]}]}, {"title": "Chloride, Week 52, n=157, 159, 67", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "spread": "2.51"}, {"groupId": "OG001", "value": "0.0", "spread": "2.67"}, {"groupId": "OG002", "value": "-0.3", "spread": "2.31"}]}]}, {"title": "CO2 content/bicarbonate, Week 12, n=171, 181, 87", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "3.13"}, {"groupId": "OG001", "value": "-0.8", "spread": "2.91"}, {"groupId": "OG002", "value": "-0.2", "spread": "2.72"}]}]}, {"title": "CO2 content/bicarbonate, Week 28, n=179, 176, 79", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.3", "spread": "2.90"}, {"groupId": "OG001", "value": "0.1", "spread": "2.61"}, {"groupId": "OG002", "value": "0.9", "spread": "2.60"}]}]}, {"title": "CO2 content/bicarbonate, Week 52, n=156, 158, 67", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "2.53"}, {"groupId": "OG001", "value": "0.1", "spread": "2.51"}, {"groupId": "OG002", "value": "0.5", "spread": "2.55"}]}]}, {"title": "Glucose, Week 12, n=172, 181, 87", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.33", "spread": "1.873"}, {"groupId": "OG001", "value": "0.17", "spread": "2.085"}, {"groupId": "OG002", "value": "0.10", "spread": "1.233"}]}]}, {"title": "Glucose, Week 28, n=180, 175, 79", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.21", "spread": "1.547"}, {"groupId": "OG001", "value": "0.16", "spread": "1.556"}, {"groupId": "OG002", "value": "0.02", "spread": "1.442"}]}]}, {"title": "Glucose, Week 52, n=157, 159, 67", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.45", "spread": "1.839"}, {"groupId": "OG001", "value": "0.11", "spread": "1.426"}, {"groupId": "OG002", "value": "-0.20", "spread": "1.191"}]}]}, {"title": "Potassium, Week 12, n=157, 165, 84", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.09", "spread": "0.572"}, {"groupId": "OG001", "value": "0.00", "spread": "0.721"}, {"groupId": "OG002", "value": "-0.03", "spread": "0.606"}]}]}, {"title": "Potassium, Week 28, n=179, 176, 79", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.12", "spread": "0.467"}, {"groupId": "OG001", "value": "-0.15", "spread": "0.449"}, {"groupId": "OG002", "value": "0.02", "spread": "0.617"}]}]}, {"title": "Potassium, Week 52, n=156, 156, 67", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.18", "spread": "0.461"}, {"groupId": "OG001", "value": "-0.12", "spread": "0.535"}, {"groupId": "OG002", "value": "-0.10", "spread": "0.446"}]}]}, {"title": "Sodium, Week 12, n=172, 182, 87", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "2.47"}, {"groupId": "OG001", "value": "0.2", "spread": "2.61"}, {"groupId": "OG002", "value": "-0.0", "spread": "2.24"}]}]}, {"title": "Sodium, Week 28, n=180, 176, 79", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "2.46"}, {"groupId": "OG001", "value": "0.2", "spread": "2.65"}, {"groupId": "OG002", "value": "0.3", "spread": "2.74"}]}]}, {"title": "Sodium, Week 52, n=157, 159, 67", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "2.57"}, {"groupId": "OG001", "value": "0.1", "spread": "2.52"}, {"groupId": "OG002", "value": "0.0", "spread": "2.80"}]}]}, {"title": "Urea/BUN, Week 12, n=172, 182, 87", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.24", "spread": "1.299"}, {"groupId": "OG001", "value": "0.36", "spread": "1.237"}, {"groupId": "OG002", "value": "0.02", "spread": "1.757"}]}]}, {"title": "Urea/BUN, Week 28, n=180, 176, 79", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.16", "spread": "1.460"}, {"groupId": "OG001", "value": "0.14", "spread": "1.124"}, {"groupId": "OG002", "value": "0.41", "spread": "2.676"}]}]}, {"title": "Urea/BUN, Week 52, n=157, 159, 67", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.15", "spread": "1.244"}, {"groupId": "OG001", "value": "0.13", "spread": "1.479"}, {"groupId": "OG002", "value": "-0.04", "spread": "1.900"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in the Percentage of Basophils, Eosinophils, Hematocrit, Lymphocytes, Monocytes, and Segmented Neutrophils in the Blood at Week 12, Week 28, and Week 52/Early Withdrawal", "description": "Blood samples were collected for the measurement of the percentage of basophils, eosinophils, hematocrit, lymphocytes, monocytes, and segmented neutrophils in the blood at the following scheduled time points: Baseline, Week 12, Week 28, and Week 52/Early Withdrawal. The Baseline value is defined as the most recent recorded value at Screening or prior to Day 1. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the ITT Population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage", "timeFrame": "Baseline; Week 12, Week 28, and Week 52/Early Withdrawal", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "101"}]}], "classes": [{"title": "Basophils, Week 12, n=171, 170, 86", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.01", "spread": "0.330"}, {"groupId": "OG001", "value": "-0.06", "spread": "0.331"}, {"groupId": "OG002", "value": "-0.08", "spread": "0.320"}]}]}, {"title": "Basophils, Week 28, n=169, 169, 77", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.01", "spread": "0.319"}, {"groupId": "OG001", "value": "0.00", "spread": "0.338"}, {"groupId": "OG002", "value": "-0.06", "spread": "0.310"}]}]}, {"title": "Basophils, Week 52, n=155, 155, 71", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.02", "spread": "0.314"}, {"groupId": "OG001", "value": "-0.03", "spread": "0.279"}, {"groupId": "OG002", "value": "-0.07", "spread": "0.319"}]}]}, {"title": "Eosinophils, Week 12, n=171, 170, 86", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.35", "spread": "4.048"}, {"groupId": "OG001", "value": "-0.88", "spread": "3.825"}, {"groupId": "OG002", "value": "-1.23", "spread": "3.391"}]}]}, {"title": "Eosinophils, Week 28, n=169, 169, 77", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.97", "spread": "3.991"}, {"groupId": "OG001", "value": "-1.34", "spread": "3.774"}, {"groupId": "OG002", "value": "-1.63", "spread": "3.574"}]}]}, {"title": "Eosinophils, Week 52, n=155, 155, 71", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.84", "spread": "4.096"}, {"groupId": "OG001", "value": "-0.90", "spread": "3.946"}, {"groupId": "OG002", "value": "-1.19", "spread": "3.611"}]}]}, {"title": "Lymphocytes, Week 12, n=171, 170, 86", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.57", "spread": "9.280"}, {"groupId": "OG001", "value": "-0.91", "spread": "8.414"}, {"groupId": "OG002", "value": "-1.72", "spread": "8.449"}]}]}, {"title": "Lymphocytes, Week 28, n=169, 169, 77", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.11", "spread": "8.816"}, {"groupId": "OG001", "value": "-1.31", "spread": "10.200"}, {"groupId": "OG002", "value": "-1.66", "spread": "11.054"}]}]}, {"title": "Lymphocytes, Week 52, n=155, 155, 71", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.34", "spread": "9.389"}, {"groupId": "OG001", "value": "-0.03", "spread": "10.137"}, {"groupId": "OG002", "value": "-0.97", "spread": "8.532"}]}]}, {"title": "Monocytes, Week 12, n=171, 170, 86", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.60", "spread": "2.692"}, {"groupId": "OG001", "value": "-0.47", "spread": "2.500"}, {"groupId": "OG002", "value": "-0.86", "spread": "3.147"}]}]}, {"title": "Monocytes, Week 28, n=169, 169, 77", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.66", "spread": "2.594"}, {"groupId": "OG001", "value": "-0.53", "spread": "2.706"}, {"groupId": "OG002", "value": "-0.84", "spread": "3.063"}]}]}, {"title": "Monocytes, Week 52, n=155, 155, 71", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.19", "spread": "2.439"}, {"groupId": "OG001", "value": "0.31", "spread": "2.598"}, {"groupId": "OG002", "value": "-0.30", "spread": "2.337"}]}]}, {"title": "Segmented neutrophils, Week 12, n=171, 170, 86", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.54", "spread": "10.883"}, {"groupId": "OG001", "value": "2.32", "spread": "9.635"}, {"groupId": "OG002", "value": "3.89", "spread": "11.397"}]}]}, {"title": "Segmented neutrophils, Week 28, n=169, 169, 77", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.71", "spread": "10.221"}, {"groupId": "OG001", "value": "3.18", "spread": "12.008"}, {"groupId": "OG002", "value": "4.19", "spread": "13.745"}]}]}, {"title": "Segmented neutrophils, Week 52, n=155, 155, 71", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.33", "spread": "10.687"}, {"groupId": "OG001", "value": "0.66", "spread": "11.768"}, {"groupId": "OG002", "value": "2.54", "spread": "10.112"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Eosinophil Count, Total Absolute Neutrophil Count (ANC), Platelet Count, and White Blood Cell (WBC) Count at Week 12, Week 28, and Week 52/Early Withdrawal", "description": "Blood samples were collected to determine the eosinophil count, total ANC, platelet count, and WBC count at the following scheduled time points: Baseline, Week 12, Week 28, and Week 52/Early Withdrawal. The Baseline value is defined as the most recent recorded value at Screening or prior to Day 1. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the ITT Population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^9 cells per liter (GI/L)", "timeFrame": "Baseline; Week 12, Week 28, and Week 52/Early Withdrawal", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"title": "Eosinophil count, Week 12, n=171, 170, 86", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.010", "spread": "0.3226"}, {"groupId": "OG001", "value": "-0.057", "spread": "0.3841"}, {"groupId": "OG002", "value": "-0.073", "spread": "0.2220"}]}]}, {"title": "Eosinophil count, Week 28, n=169, 169, 77", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.039", "spread": "0.3310"}, {"groupId": "OG001", "value": "-0.083", "spread": "0.3698"}, {"groupId": "OG002", "value": "-0.083", "spread": "0.2363"}]}]}, {"title": "Eosinophil count, Week 52, n=155, 155, 71", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.023", "spread": "0.3273"}, {"groupId": "OG001", "value": "-0.037", "spread": "0.3171"}, {"groupId": "OG002", "value": "-0.044", "spread": "0.2539"}]}]}, {"title": "Total ANC, Week 12, n=171, 170, 86", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.392", "spread": "1.6161"}, {"groupId": "OG001", "value": "0.469", "spread": "1.6904"}, {"groupId": "OG002", "value": "0.493", "spread": "1.7488"}]}]}, {"title": "Total ANC, Week 28, n=169, 169, 77", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.632", "spread": "1.5922"}, {"groupId": "OG001", "value": "0.679", "spread": "2.0157"}, {"groupId": "OG002", "value": "0.750", "spread": "2.0130"}]}]}, {"title": "Total ANC, Week 52, n=136, 136, 60", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.524", "spread": "1.4589"}, {"groupId": "OG001", "value": "0.612", "spread": "1.9100"}, {"groupId": "OG002", "value": "0.748", "spread": "1.7946"}]}]}, {"title": "Platelet Count, Week 12, n=167, 159, 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.3", "spread": "39.44"}, {"groupId": "OG001", "value": "1.5", "spread": "68.10"}, {"groupId": "OG002", "value": "1.5", "spread": "43.26"}]}]}, {"title": "Platelet Count, Week 28, n=164, 165, 74", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.0", "spread": "44.49"}, {"groupId": "OG001", "value": "3.5", "spread": "35.06"}, {"groupId": "OG002", "value": "12.4", "spread": "43.59"}]}]}, {"title": "Platelet Count, Week 52, n=147, 151, 68", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.8", "spread": "43.80"}, {"groupId": "OG001", "value": "4.6", "spread": "38.49"}, {"groupId": "OG002", "value": "16.4", "spread": "50.99"}]}]}, {"title": "WBC Count, Week 12, n=173, 170, 86", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.51", "spread": "1.744"}, {"groupId": "OG001", "value": "0.50", "spread": "2.007"}, {"groupId": "OG002", "value": "0.39", "spread": "1.906"}]}]}, {"title": "WBC Count, Week 28, n=170, 169, 77", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.74", "spread": "1.758"}, {"groupId": "OG001", "value": "0.74", "spread": "2.103"}, {"groupId": "OG002", "value": "0.79", "spread": "2.028"}]}]}, {"title": "WBC Count, Week 52, n=156, 156, 71", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.91", "spread": "1.639"}, {"groupId": "OG001", "value": "0.83", "spread": "2.046"}, {"groupId": "OG002", "value": "1.01", "spread": "1.909"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Hematocrit at Week 12, Week 28, and Week 52/Early Withdrawal", "description": "Blood samples were collected for the measurement of hematocrit values at the following scheduled time points: Baseline, Week 12, Week 28, and Week 52/Early Withdrawal. The Baseline value is defined as the most recent recorded value at Screening or prior to Day 1. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Proportion of 1.0", "timeFrame": "Baseline; Week 12, Week 28, and Week 52/Early Withdrawal", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"title": "Week 12, n=176, 172, 86", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.0073", "spread": "0.02307"}, {"groupId": "OG001", "value": "-0.0013", "spread": "0.02654"}, {"groupId": "OG002", "value": "-0.0025", "spread": "0.02318"}]}]}, {"title": "Week 28, n=172, 170, 77", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.0017", "spread": "0.02213"}, {"groupId": "OG001", "value": "-0.0005", "spread": "0.02464"}, {"groupId": "OG002", "value": "-0.0028", "spread": "0.02168"}]}]}, {"title": "Week 52, n=157, 159, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.0027", "spread": "0.02906"}, {"groupId": "OG001", "value": "-0.0021", "spread": "0.02467"}, {"groupId": "OG002", "value": "-0.0045", "spread": "0.02495"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Hemoglobin at Week 12, Week 28, and Week 52/Early Withdrawal", "description": "Blood samples were collected for the measurement of hemoglobin values at the following scheduled time points: Baseline, Week 12, Week 28, and Week 52/Early Withdrawal. The Baseline value is defined as the most recent recorded value at Screening or prior to Day 1. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Grams per liter (g/L)", "timeFrame": "Baseline; Week 12, Week 28, and Week 52/Early Withdrawal", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participnts were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albutero/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"title": "Week 12, n=176, 172, 86", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.4", "spread": "7.48"}, {"groupId": "OG001", "value": "-1.8", "spread": "8.25"}, {"groupId": "OG002", "value": "-2.0", "spread": "7.67"}]}]}, {"title": "Week 28, n=172, 170, 77", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.1", "spread": "7.64"}, {"groupId": "OG001", "value": "-2.2", "spread": "8.11"}, {"groupId": "OG002", "value": "-2.4", "spread": "7.72"}]}]}, {"title": "Week 52, n=157, 159, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.6", "spread": "10.26"}, {"groupId": "OG001", "value": "-2.9", "spread": "7.47"}, {"groupId": "OG002", "value": "-3.0", "spread": "8.77"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With the Indicated Shift From Baseline to High, Normal or no Change, and Low Post-Baseline Values for Urinary Cortisol Excretion", "description": "A 24-hour urine sample was collected for the measurement of 24-hour urinary cortisol excretion (UCE) at the following scheduled time points: Baseline, Week 12, Week 28, and Week 52/Early Withdrawal. Any visit post-baseline (AVPB) value was derived using laboratory assessments performed at scheduled, unscheduled, and Early Withdrawal visits. Participants who had a shift from Baseline in their post-Baseline UCE values relative to the normal range, are presented in the \"To high and To low\" categories. Participants whose post-Baseline UCE values were unchanged (e.g., High to High) or whose value became normal, are presented in the \"To normal or no change\" category. The normal range for UCE is defined as: 11 to 138 nanomoles per 24 hours (nmol/24 hr) for participants \\>=18 years of age, 8.3 to 151.7 nmol/24 hr for participants 14 to 17 years of age, and 2.8 to 124.2 nmol/24 hr for participants 12 and 13 years of age.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline; Week 12, Week 28, and Week 52/Early Withdrawal", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"title": "Week 12: To high, n=139, 140, 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "6", "lowerLimit": "4.5", "upperLimit": "160.6"}, {"groupId": "OG001", "value": "7", "lowerLimit": "5.9", "upperLimit": "491.8"}, {"groupId": "OG002", "value": "2", "lowerLimit": "5.3", "upperLimit": "780.5"}]}]}, {"title": "Week 12: To normal or no change, n=139, 140, 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "131", "lowerLimit": "5.7", "upperLimit": "547.4"}, {"groupId": "OG001", "value": "128", "lowerLimit": "6.1", "upperLimit": "482.5"}, {"groupId": "OG002", "value": "67", "lowerLimit": "3.8", "upperLimit": "667.5"}]}]}, {"title": "Week 12: To low, n=139, 140, 78", "categories": [{"measurements": [{"groupId": "OG000", "value": "2", "lowerLimit": "4.0", "upperLimit": "602.3"}, {"groupId": "OG001", "value": "5", "lowerLimit": "10.4", "upperLimit": "549.6"}, {"groupId": "OG002", "value": "9", "lowerLimit": "3.4", "upperLimit": "396.4"}]}]}, {"title": "Week 28: To high, n=135, 131, 59", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Week 28: To normal or no change, n=135, 131, 59", "categories": [{"measurements": [{"groupId": "OG000", "value": "123"}, {"groupId": "OG001", "value": "120"}, {"groupId": "OG002", "value": "47"}]}]}, {"title": "Week 28: To low, n=135, 131, 59", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "9"}]}]}, {"title": "Week 52: To high, n=134, 140, 65", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Week 52: To normal or no change , n=134, 140, 65", "categories": [{"measurements": [{"groupId": "OG000", "value": "119"}, {"groupId": "OG001", "value": "131"}, {"groupId": "OG002", "value": "57"}]}]}, {"title": "Week 52: To low, n=134, 140, 65", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "AVBP: To high, n=156, 156, 83", "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "21"}, {"groupId": "OG002", "value": "8"}]}]}, {"title": "AVBP: To normal or no change, n=156, 156, 83", "categories": [{"measurements": [{"groupId": "OG000", "value": "119"}, {"groupId": "OG001", "value": "126"}, {"groupId": "OG002", "value": "58"}]}]}, {"title": "AVBP: To low, n=156, 156, 83", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "17"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Ratio", "paramValue": "1.67", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.34", "ciUpperLimit": "2.08", "estimateComment": "Ratio of FF/VI 100/25 OD versus FP 500 BD to Baseline of 24-Hour Urinary Cortisol Excretion at Week 12"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Ratio", "paramValue": "1.65", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.29", "ciUpperLimit": "2.13", "estimateComment": "Ratio of FF/VI 100/25 OD versus FP 500 BD to Baseline of 24-Hour Urinary Cortisol Excretion at Week 28"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Ratio", "paramValue": "1.05", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.83", "ciUpperLimit": "1.33", "estimateComment": "Ratio of FF/VI 100/25 OD versus FP 500 BD to Baseline of 24-Hour Urinary Cortisol Excretion at Week 52"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Ratio", "paramValue": "1.52", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.22", "ciUpperLimit": "1.89", "estimateComment": "Ratio of FF/VI 200/25 OD versus FP 500 BD to Baseline of 24-Hour Urinary Cortisol Excretion at Week 12"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Ratio", "paramValue": "1.43", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.11", "ciUpperLimit": "1.84", "estimateComment": "Ratio of FF/VI 200/25 OD versus FP 500 BD to Baseline of 24-Hour Urinary Cortisol Excretion at Week 28"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Ratio", "paramValue": "1.09", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.87", "ciUpperLimit": "1.38", "estimateComment": "Ratio of FF/VI 200/25 OD versus FP 500 BD to Baseline of 24-Hour Urinary Cortisol Excretion at Week 52"}]}, {"type": "PRIMARY", "title": "Ratio of 24-hour Urinary Cortisol Excretion at Week 12 to Baseline", "description": "A 24-hour urine sample was collected, and the least square geometric mean (LSGM) for 24-hour urinary cortisol excretion (UCE) was calculated at Baseline and at Week 12. The ratio of the Week 12 LSGM to the Baseline LSGM was calculated as the value at Week 12 divided by the value at Baseline. Analysis was performed using analysis of covariance (ANCOVA) with covariates of region, sex, age, treatment, and the log of the Baseline values.", "populationDescription": "Urinary cortisol (UC) Population: participants in the ITT Population whose urine samples did not have confounding factors that affected the interpretation of results. These participants were determined prior to breaking the blind. Only those participants available at the specified time point were analyzed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Ratio of LSGM of UCE to Baseline", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "129"}, {"groupId": "OG001", "value": "129"}, {"groupId": "OG002", "value": "71"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.03"}, {"groupId": "OG001", "value": "0.93"}, {"groupId": "OG002", "value": "0.61"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Ratio of LSGM to Baseline", "paramValue": "1.67", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.34", "ciUpperLimit": "2.08"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Ratio of LSGM to Baseline", "paramValue": "1.52", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.22", "ciUpperLimit": "1.89"}]}, {"type": "PRIMARY", "title": "Ratio of 24-hour Urinary Cortisol Excretion at Week 28 to Baseline", "description": "A 24-hour urine sample was collected, and the LSGM for 24-hour UCE was calculated at Baseline and at Week 28. The ratio of the Week 28 LSGM to the Baseline LSGM was calculated as the value at Week 28 divided by the value at Baseline. Analysis was performed using ANCOVA with covariates of region, sex, age, treatment, and the log of the Baseline values.", "populationDescription": "UC Population. Only those participants available at the specified time point were analyzed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Ratio of LSGM of UCE to Baseline", "timeFrame": "Baseline and Week 28", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "121"}, {"groupId": "OG002", "value": "56"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.05"}, {"groupId": "OG001", "value": "0.91"}, {"groupId": "OG002", "value": "0.64"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Ratio of LSGM to Baseline", "paramValue": "1.65", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.29", "ciUpperLimit": "2.13"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.006", "statisticalMethod": "ANCOVA", "paramType": "Ratio of LSGM to Baseline", "paramValue": "1.43", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.11", "ciUpperLimit": "1.84"}]}, {"type": "PRIMARY", "title": "Ratio of 24-hour Urinary Cortisol Excretion at Week 52 to Baseline", "description": "A 24-hour urine sample was collected, and the LSGM for 24-hour UCE was calculated at Baseline and at Week 52. The ratio of the Week 52 LSGM to the Baseline LSGM was calculated as the value at Week 52 divided by the value at Baseline. Analysis was performed using ANCOVA with covariates of region, sex, age, treatment, and the log of the Baseline values.", "populationDescription": "UC Population. Only those participants available at the specified time point were analyzed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Ratio of LSGM of UCE to Baseline", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "125"}, {"groupId": "OG001", "value": "127"}, {"groupId": "OG002", "value": "60"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.00"}, {"groupId": "OG001", "value": "1.04"}, {"groupId": "OG002", "value": "0.95"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.674", "statisticalMethod": "ANCOVA", "paramType": "Ratio of LSGM to Baseline", "paramValue": "1.05", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.83", "ciUpperLimit": "1.33"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.444", "statisticalMethod": "ANCOVA", "paramType": "Ratio of LSGM to Baseline", "paramValue": "1.09", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.87", "ciUpperLimit": "1.38"}]}, {"type": "PRIMARY", "title": "Number of Participants With Evidence of Oral Candidiasis at Any Time Post-Baseline", "description": "A detailed oropharyngeal examination was done at all clinic visits for visual/clinical evidence of oral candidiasis over the entire Treatment Period (worst case any time post-Baseline). For participants with visual/clinical evidence of candidiasis during the Treatment Phase of the study, a culture swab was taken and analyzed for infection.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "From Baseline until Visit 11/Early Withdrawal (52 weeks)", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "199"}, {"groupId": "OG001", "value": "200"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"title": "Evidence of oral candidiasis", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "5"}]}]}, {"title": "Positive culture swab", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Negative culture swab", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "No swab result available", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Maximum Change From Baseline in Systolic Blood Pressure (SBP) and Minimum Change From Baseline in Diastolic Blood Pressure (DBP)", "description": "SBP and DBP were measured at the following scheduled time points: Screening, Day 1, Week 2, Week 4, Week 8, Week 12, Week 20, Week 28, Week 36, Week 44, and Week 52/Early Withdrawal. Baseline is defined as the Visit 1 (screening) value. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline. Maximum and minimum change from Baseline for any post-Baseline visit was derived using all scheduled, unscheduled, and Early Withdrawal visits.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Millimeters of mercury (mmHg)", "timeFrame": "From Baseline until Visit 11/Early Withdrawal (52 weeks)", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"title": "Maximum post-Baseline change in SBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.2", "spread": "11.05"}, {"groupId": "OG001", "value": "10.0", "spread": "10.17"}, {"groupId": "OG002", "value": "11.3", "spread": "11.09"}]}]}, {"title": "Minimum post-Baseline change in DBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.9", "spread": "7.70"}, {"groupId": "OG001", "value": "-9.0", "spread": "8.44"}, {"groupId": "OG002", "value": "-8.0", "spread": "7.76"}]}]}]}, {"type": "PRIMARY", "title": "Maximum Change From Baseline in Pulse Rate", "description": "Pulse rate was measured at the following scheduled time points: Screening, Day 1, Week 2, Week 4, Week 8, Week 12, Week 20,Week 28, Week 36, Week 44, and Week 52/Early Withdrawal. Baseline is defined as the Visit 1 (screening) value. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline. Maximum change from Baseline for any post-Baseline visit was derived using all scheduled, unscheduled, and Early Withdrawal visits.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Beats per minute", "timeFrame": "From Baseline until Visit 11/Early Withdrawal (52 weeks)", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.5", "spread": "9.30"}, {"groupId": "OG001", "value": "10.0", "spread": "10.05"}, {"groupId": "OG002", "value": "7.5", "spread": "8.29"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With the Indicated Change From Baseline in Lens Opacities Classification System, Version III (LOCS III) Posterior Subcapsular Opacity (P) at Week 28 and Week 52", "description": "P is defined as the opacification at the back of the lens adjacent to the capsule (or bag) in which the lens sits. An event of P is defined as an increase of \\>=0.3 from Baseline in LOCS III grade for P in either eye at any time post-Baseline. Per LOC III, P ranges from 0.1 (clear or colorless) to 5.9 (very opaque). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline; Week 28, and Week 52", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"title": "Left eye, <0.3, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "174"}, {"groupId": "OG001", "value": "175"}, {"groupId": "OG002", "value": "79"}]}]}, {"title": "Left eye, >=0.3 and <0.5, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Left eye, >=0.5, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Right eye, <0.3, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "175"}, {"groupId": "OG001", "value": "175"}, {"groupId": "OG002", "value": "80"}]}]}, {"title": "Right eye, >=0.3 and <0.5, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Right eye, >=0.5, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Left eye, <0.3, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "163"}, {"groupId": "OG001", "value": "164"}, {"groupId": "OG002", "value": "72"}]}]}, {"title": "Left eye, >=0.3 and <0.5, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Left eye, >=0.5, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Right eye, <0.3, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "163"}, {"groupId": "OG001", "value": "164"}, {"groupId": "OG002", "value": "72"}]}]}, {"title": "Right eye, >=0.3 and <0.5, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Right eye, >=0.5, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With the Indicated Change From Baseline in Intraocular Pressure (IOP) at Week 28 and Week 52", "description": "Intraocular pressure (IOP) is the fluid pressure inside the eye. IOP was measured twice for each eye at Baseline, Week 28, and Week 52 using Goldmann Applanation tonometry. The second IOP reading was used for analysis. The number of participants with a change from Baseline in IOP of \\<0 mmHg, \\>=0 to \\<4 mmHg, \\>=4 to \\<7 mmHg, \\>=7 to \\<11 mmHg, and \\>=11 mmHg are presented. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline; Week 28 and Week 52", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"title": "Left eye, <0 mmHg, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "78"}, {"groupId": "OG002", "value": "32"}]}]}, {"title": "Left eye, >=0 to <4 mmHg, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "101"}, {"groupId": "OG001", "value": "92"}, {"groupId": "OG002", "value": "46"}]}]}, {"title": "Left eye, >=4 to <7 mmHg, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Left eye, >=7 to <11 mmHg, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Left eye, >=11 mmHg, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Right eye, <0 mmHg, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "38"}]}]}, {"title": "Right eye, >=0 to <4 mmHg, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "101"}, {"groupId": "OG001", "value": "110"}, {"groupId": "OG002", "value": "38"}]}]}, {"title": "Right eye, >=4 to <7 mmHg, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Right eye, >=7 to <11 mmHg,Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Right eye, >=11 mmHg, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Left eye, <0 mmHg, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "33"}]}]}, {"title": "Left eye, >=0 to <4 mmHg, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "83"}, {"groupId": "OG002", "value": "36"}]}]}, {"title": "Left eye, >=4 to <7 mmHg, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Left eye, >=7 to <11 mmHg, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Left eye, >=11 mmHg, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Right eye, <0 mmHg, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "32"}]}]}, {"title": "Right eye, >=0 to <4 mmHg, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "94"}, {"groupId": "OG001", "value": "93"}, {"groupId": "OG002", "value": "40"}]}]}, {"title": "Right eye, >=4 to <7 mmHg, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Right eye, >=7 to <11 mmHg, Week 52, n=167,166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Right eye, >=11 mmHg, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Horizontal Cup-to-disc Ratio at Week 28 and Week 52", "description": "Funduscopic examination was performed at Baseline, Week 28, and Week 52 to measure the horizontal cup-to-disc ratio of both eyes. The horizontal cup-to-disc ratio is the ratio of the horizontal diameter of the physiological cup to that of the horizontal diameter of the optic disc. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ratio", "timeFrame": "Baseline; Week 28 and Week 52", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"title": "Left eye, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.5", "spread": "4.79"}, {"groupId": "OG001", "value": "-0.2", "spread": "5.11"}, {"groupId": "OG002", "value": "0.5", "spread": "4.87"}]}]}, {"title": "Right eye, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.2", "spread": "4.17"}, {"groupId": "OG001", "value": "-0.2", "spread": "6.49"}, {"groupId": "OG002", "value": "0.5", "spread": "5.10"}]}]}, {"title": "Left eye, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.4", "spread": "5.86"}, {"groupId": "OG001", "value": "0.2", "spread": "4.89"}, {"groupId": "OG002", "value": "0.3", "spread": "4.77"}]}]}, {"title": "Right eye, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "4.63"}, {"groupId": "OG001", "value": "0.2", "spread": "5.57"}, {"groupId": "OG002", "value": "0.0", "spread": "5.26"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With the Indicated Change From Baseline in Lens Opacities Classification System, Version III (LOCS III) Cortical Opacity (C) at Week 28 and Week 52", "description": "C is defined as the opacification of the cortex (outer layer) of the lens. Per LOC III, C ranges from 0.1 (clear or colorless) to 5.9 (very opaque). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline; Week 28 and Week 52", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"title": "Left eye, <0.3, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "167"}, {"groupId": "OG001", "value": "166"}, {"groupId": "OG002", "value": "75"}]}]}, {"title": "Left eye, >=0.3 and <0.5, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Left eye, >=0.5, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Right eye, <0.3, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "169"}, {"groupId": "OG001", "value": "172"}, {"groupId": "OG002", "value": "75"}]}]}, {"title": "Right eye, >=0.3 and <0.5, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Right eye, >=0.5, Week 28, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Left eye, <0.3, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "156"}, {"groupId": "OG002", "value": "66"}]}]}, {"title": "Left eye, >=0.3 and <0.5, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Left eye, >=0.5, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Right eye, <0.3, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "158"}, {"groupId": "OG002", "value": "69"}]}]}, {"title": "Right eye, >=0.3 and <0.5, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Right eye, >=0.5, Week 52, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "1"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Lens Opacities Classification System, Version III (LOCS III) Nuclear Color (NC) at Week 28 and Week 52", "description": "NC is the color of the nucleus (central layer) of the lens. Per LOC III, NC ranges from 0.1 (clear or colorless) to 6.9 (very opaque or brunescent). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline; Week 28 and Week 52", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"title": "Week 28, Left eye, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.01", "spread": "0.282"}, {"groupId": "OG001", "value": "0.00", "spread": "0.284"}, {"groupId": "OG002", "value": "-0.02", "spread": "0.299"}]}]}, {"title": "Week 28, Right eye, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.01", "spread": "0.292"}, {"groupId": "OG001", "value": "0.1", "spread": "0.292"}, {"groupId": "OG002", "value": "-0.02", "spread": "0.294"}]}]}, {"title": "Week 52, Left eye, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.02", "spread": "0.281"}, {"groupId": "OG001", "value": "-0.2", "spread": "0.357"}, {"groupId": "OG002", "value": "0.00", "spread": "0.340"}]}]}, {"title": "Week 52, Right eye, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.02", "spread": "0.304"}, {"groupId": "OG001", "value": "0.00", "spread": "0.339"}, {"groupId": "OG002", "value": "0.01", "spread": "0.336"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Lens Opacities Classification System, Version III (LOCS III) Nuclear Opalescence (NO) at Week 28 and Week 52", "description": "NO is the opalescence of the nucleus (central layer) of the lens. Per LOC III, NO ranges from 0.1 (clear or colorless) to 6.9 (very opaque or brunescent). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline; Week 28 and Week 52", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"title": "Week 28, Left eye, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.02", "spread": "0.236"}, {"groupId": "OG001", "value": "0.03", "spread": "0.316"}, {"groupId": "OG002", "value": "-0.02", "spread": "0.270"}]}]}, {"title": "Week 28, Right eye, n=179, 177, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.01", "spread": "0.256"}, {"groupId": "OG001", "value": "0.03", "spread": "0.303"}, {"groupId": "OG002", "value": "-0.03", "spread": "0.272"}]}]}, {"title": "Week 52, Left eye, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.01", "spread": "0.330"}, {"groupId": "OG001", "value": "0.03", "spread": "0.303"}, {"groupId": "OG002", "value": "0.01", "spread": "0.369"}]}]}, {"title": "Week 52, Right eye, n=167, 166, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "spread": "0.351"}, {"groupId": "OG001", "value": "0.04", "spread": "0.282"}, {"groupId": "OG002", "value": "0.02", "spread": "0.371"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in the Logarithm of the Minimum Angle of Resolution (LogMAR) Visual Acuity at Week 28 and Week 52", "description": "Visual acuity is defined as the acuteness or clearness of vision. The minimum angle of resolution (MAR) is the angle a viewed object subtends at the eye, usually stated in degrees/minutes of arc. Visual acuity was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) charts in decimal numbers. The LogMAR scale is used to express the visual acuity in a linear scale as the logarithm to base 10 of the MAR. A lower score indicates better visual acuity; visual acuity decreases with an increasing score. Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline; Week 28 and Week 52", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"title": "Week 28, Left eye, n=179, 176, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.008", "spread": "0.0723"}, {"groupId": "OG001", "value": "-0.010", "spread": "0.0706"}, {"groupId": "OG002", "value": "-0.004", "spread": "0.0685"}]}]}, {"title": "Week 28, Right eye, n=179, 176, 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.003", "spread": "0.0739"}, {"groupId": "OG001", "value": "-0.001", "spread": "0.0699"}, {"groupId": "OG002", "value": "-0.008", "spread": "0.0584"}]}]}, {"title": "Week 52, Left eye, n=167, 165, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.011", "spread": "0.0747"}, {"groupId": "OG001", "value": "-0.012", "spread": "0.0739"}, {"groupId": "OG002", "value": "-0.007", "spread": "0.0638"}]}]}, {"title": "Week 52, Right eye, n=167, 165, 72", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.008", "spread": "0.0928"}, {"groupId": "OG001", "value": "0.003", "spread": "0.0755"}, {"groupId": "OG002", "value": "-0.012", "spread": "0.0776"}]}]}]}, {"type": "PRIMARY", "title": "Maximum Change From Baseline in the QT Interval Using Bazett's Correction (QTcB) and QT Interval Using Fridericia's Correction (QTcF)", "description": "The QT interval is an electrocardiogram (ECG) parameter that represents the electrical depolarization and repolarization of the left and right ventricles of the heart. The QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the ECG. Corrected QT (QTc) is the QT interval corrected for heart rate by using Bazett's formula (QTcB) and Fridericia's formula (QTcF). 12-lead ECG measurements were perfomed at the following scheduled time points: Baseline; Week 2, Week 12, Week 28, and Week 52/Early Withdrawal. The Baseline value is defined as the value taken pre-dose at screening. The maximum post-Baseline value was derived using all scheduled, unscheduled, and Early Withdrawal ECG assessments. Maximum change from Baseline was calculated as the maximum post-Baseline value minus the value at Baseline.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Milliseconds (msec)", "timeFrame": "Baseline; Week 2, Week 12, Week 28, and Week 52/Early Withdrawal", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "199"}, {"groupId": "OG001", "value": "198"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"title": "QTcB", "categories": [{"measurements": [{"groupId": "OG000", "value": "19.0", "spread": "17.33"}, {"groupId": "OG001", "value": "16.4", "spread": "19.49"}, {"groupId": "OG002", "value": "13.2", "spread": "16.57"}]}]}, {"title": "QTcF", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.8", "spread": "14.51"}, {"groupId": "OG001", "value": "11.6", "spread": "15.60"}, {"groupId": "OG002", "value": "11.4", "spread": "12.81"}]}]}]}, {"type": "PRIMARY", "title": "Mean 24 Hour Holter Heart Rate for Participants With at Least 16 Hours of Recorded Data", "description": "Twenty-four hour Holter monitors were obtained using a 12-lead Holter monitor. The Holter monitor is worn by the participant for 24 hours, and the monitor continuously records the heart's rhythm while the monitor is worn. At the end of the 24 hour period, the data from the monitor are downloaded and transmitted to the centralized vendor for analysis and interpretation by a licensed cardiologist.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "beats per minute", "timeFrame": "0-24 hours at Screening, Day 1, Week 28, and Week 52", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"title": "Screening, n=111, 116, 49", "categories": [{"measurements": [{"groupId": "OG000", "value": "79.0", "spread": "8.23"}, {"groupId": "OG001", "value": "79.1", "spread": "9.55"}, {"groupId": "OG002", "value": "79.8", "spread": "8.75"}]}]}, {"title": "Day 1, n=104, 113, 47", "categories": [{"measurements": [{"groupId": "OG000", "value": "78.6", "spread": "7.89"}, {"groupId": "OG001", "value": "78.7", "spread": "9.45"}, {"groupId": "OG002", "value": "77.4", "spread": "7.66"}]}]}, {"title": "Week 28, n=95, 90, 39", "categories": [{"measurements": [{"groupId": "OG000", "value": "77.8", "spread": "8.90"}, {"groupId": "OG001", "value": "77.5", "spread": "9.01"}, {"groupId": "OG002", "value": "74.9", "spread": "8.54"}]}]}, {"title": "Week 52, n=88, 82, 37", "categories": [{"measurements": [{"groupId": "OG000", "value": "78.8", "spread": "8.72"}, {"groupId": "OG001", "value": "78.0", "spread": "10.15"}, {"groupId": "OG002", "value": "74.8", "spread": "8.62"}]}]}]}, {"type": "PRIMARY", "title": "Maximum 24 Hour Holter Heart Rate for Participants With at Least 16 Hours of Recorded Data", "description": "Twenty-four hour Holter monitors were obtained using a 12-lead Holter monitor. Holter monitor data were transmitted to a centralized vendor for analysis and interpretation by a licensed cardiologist.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "beats per minute", "timeFrame": "0-24 hours at Screening, Day 1, Week 28, and Week 52", "groups": [{"id": "OG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FP 500 \u00b5g BID", "description": "Participants received FP 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"title": "Screening, n=111, 116, 49", "categories": [{"measurements": [{"groupId": "OG000", "value": "132.6", "spread": "17.18"}, {"groupId": "OG001", "value": "132.1", "spread": "17.85"}, {"groupId": "OG002", "value": "133.0", "spread": "16.17"}]}]}, {"title": "Day 1, n=104, 113, 47", "categories": [{"measurements": [{"groupId": "OG000", "value": "131.2", "spread": "18.28"}, {"groupId": "OG001", "value": "130.8", "spread": "19.50"}, {"groupId": "OG002", "value": "129.2", "spread": "18.77"}]}]}, {"title": "Week 28, n=95, 90, 39", "categories": [{"measurements": [{"groupId": "OG000", "value": "127.5", "spread": "17.93"}, {"groupId": "OG001", "value": "127.4", "spread": "16.62"}, {"groupId": "OG002", "value": "123.5", "spread": "14.93"}]}]}, {"title": "Week 52, n=88, 82, 37", "categories": [{"measurements": [{"groupId": "OG000", "value": "126.9", "spread": "18.16"}, {"groupId": "OG001", "value": "128.1", "spread": "16.63"}, {"groupId": "OG002", "value": "122.8", "spread": "13.89"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication until Follow-up (up to 52 weeks of treatment).", "description": "SAEs and non-serious AEs were collected in the Intent-to-Treat (ITT) Population, comprised of all participants randomized to treatment who received at least one dose of study medication.", "eventGroups": [{"id": "EG000", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF)/Vilanterol (VI) 100/25 micrograms (\u00b5g) inhalation powder once daily (OD) in the evening via the Dry Powder Inhaler (DPI), plus a placebo via DISKUS/ACCUHALER twice daily (BID), for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period.", "seriousNumAffected": 3, "seriousNumAtRisk": 201, "otherNumAffected": 108, "otherNumAtRisk": 201}, {"id": "EG001", "title": "FF/VI 200/25 \u00b5g OD", "description": "Participants received FF/VI 200/25 \u00b5g inhalation powder OD in the evening via the DPI, plus a placebo via DISKUS/ACCUHALER BID, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period.", "seriousNumAffected": 1, "seriousNumAtRisk": 202, "otherNumAffected": 105, "otherNumAtRisk": 202}, {"id": "EG002", "title": "FP 500 \u00b5g BD", "description": "Participants received Fluticasone Propionate (FP) 500 \u00b5g BID via DISKUS/ACCUHALER, plus a placebo via the DPI OD in the evening, for 52 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period.", "seriousNumAffected": 7, "seriousNumAtRisk": 100, "otherNumAffected": 61, "otherNumAtRisk": 100}], "seriousEvents": [{"term": "Dengue Fever", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 100}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 100}]}, {"term": "Pyelonephritis Acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 100}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 100}]}, {"term": "Breast Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 100}]}, {"term": "Fibroadenoma of Breast", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 100}]}, {"term": "Hepatitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 100}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 100}]}, {"term": "Deep Vein Thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 100}]}], "otherEvents": [{"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 34, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 30, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 18, "numAtRisk": 100}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 25, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 19, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 10, "numAtRisk": 100}]}, {"term": "Oral candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 100}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 100}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 100}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 100}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 39, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 35, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 23, "numAtRisk": 100}]}, {"term": "Tension headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 100}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 13, "numAtRisk": 100}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 11, "numAtRisk": 100}]}, {"term": "Dysphonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 100}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 100}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 100}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 100}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 100}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 100}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 100}]}, {"term": "Extrasystoles", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 100}]}, {"term": "Ear pain", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 100}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}